-
公开(公告)号：US20070155808A1
公开(公告)日：2007-07-05
申请号：US10584730
申请日：2004-12-24
申请人： Tsuneo Yasuma , Shinobu Sasaki , Nozomu Sakai
发明人： Tsuneo Yasuma , Shinobu Sasaki , Nozomu Sakai
IPC分类号： A61K31/426 , A61K31/421
CPC分类号： C07D277/42 , C07D263/48 , C07D417/04 , C07D417/12
摘要： The present invention provides a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, a drug for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof have unexpectedly superior GPR40 receptor agonist activity and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful drugs for the prophylaxis or treatment of GPR40 receptor related conditions or diseases in mammals.
摘要翻译： 本发明提供具有GPR40受体功能调节作用的新化合物，其可用作胰岛素促分泌素，用于预防或治疗糖尿病等的药物。 由式（I）表示的化合物，其中每个符号如说明书中所定义，其盐和前药具有出人意料的优异的GPR40受体激动剂活性，并且还表现出作为药物的优异性质，例如稳定性等。 因此，它们可以是用于预防或治疗哺乳动物中GPR40受体相关病症或疾病的安全有用的药物。
-
公开(公告)号：US07585880B2
公开(公告)日：2009-09-08
申请号：US10584730
申请日：2004-12-24
申请人： Tsuneo Yasuma , Shinobu Sasaki , Nozomu Sakai
发明人： Tsuneo Yasuma , Shinobu Sasaki , Nozomu Sakai
IPC分类号： A61K31/443 , A61K31/4439 , A61K31/427 , A61K31/422 , C07D277/22 , C07D263/32 , C07D417/10 , C07D413/10
CPC分类号： C07D277/42 , C07D263/48 , C07D417/04 , C07D417/12
摘要： The present invention provides a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, a drug for the prophylaxis or treatment of diabetes and the like.A compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof have unexpectedly superior GPR40 receptor agonist activity and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful drugs for the prophylaxis or treatment of GPR40 receptor related conditions or diseases in mammals.
摘要翻译： 本发明提供具有GPR40受体功能调节作用的新化合物，其可用作胰岛素促分泌素，用于预防或治疗糖尿病等的药物。 由式（I）表示的化合物，其中每个符号如说明书中所定义，其盐和前药具有出人意料的优异的GPR40受体激动剂活性，并且还表现出作为药物的优异性质，例如稳定性等。 因此，它们可以是用于预防或治疗哺乳动物中GPR40受体相关病症或疾病的安全有用的药物。
-
公开(公告)号：US20070213364A1
公开(公告)日：2007-09-13
申请号：US10594996
申请日：2005-03-28
申请人： Tsuneo Yasuma , Shuji Kitamura , Nozomu Sakai
发明人： Tsuneo Yasuma , Shuji Kitamura , Nozomu Sakai
IPC分类号： A61K31/47 , A61K31/4439 , A61K31/415 , A61K31/404 , A61K31/40 , A61K31/381 , C07D403/02
CPC分类号： A61K31/381 , A61K31/40 , A61K31/402 , A61K31/404 , A61K31/415 , A61K31/4174 , A61K31/4184 , A61K31/4439 , A61K31/445 , A61K31/4453 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/554 , C07D207/325 , C07D209/08 , C07D211/46 , C07D215/06 , C07D231/12 , C07D333/56 , C07D401/12 , C07D403/04 , C07D513/04
摘要： The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.
摘要翻译： 本发明旨在提供具有GPR40受体功能调节作用的新化合物，其可用作胰岛素促分泌素，用于预防或治疗糖尿病等的药剂。 由下式表示的化合物：其中每个符号如本说明书中所定义，其盐及其前药意外地具有优异的GPR40受体激动活性和作为稳定性等药物的优异性能， 并且可以是安全有用的药剂作为预防或治疗哺乳动物中GPR40受体相关病理学或疾病的药剂。
-
公开(公告)号：US07517910B2
公开(公告)日：2009-04-14
申请号：US10594996
申请日：2005-03-28
申请人： Tsuneo Yasuma , Shuji Kitamura , Nozomu Sakai
发明人： Tsuneo Yasuma , Shuji Kitamura , Nozomu Sakai
IPC分类号： A61K31/192 , C07C61/12
CPC分类号： A61K31/381 , A61K31/40 , A61K31/402 , A61K31/404 , A61K31/415 , A61K31/4174 , A61K31/4184 , A61K31/4439 , A61K31/445 , A61K31/4453 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/554 , C07D207/325 , C07D209/08 , C07D211/46 , C07D215/06 , C07D231/12 , C07D333/56 , C07D401/12 , C07D403/04 , C07D513/04
摘要： The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.
摘要翻译： 本发明旨在提供具有GPR40受体功能调节作用的新化合物，其可用作胰岛素促分泌素，用于预防或治疗糖尿病等的药剂。 由下式表示的化合物：其中每个符号如本说明书中所定义，其盐及其前药意外地具有优异的GPR40受体激动活性和作为稳定性等药物的优异性能， 并且可以是安全有用的药剂作为预防或治疗哺乳动物中GPR40受体相关病理学或疾病的药剂。
-
公开(公告)号：US20130116214A1
公开(公告)日：2013-05-09
申请号：US13810021
申请日：2011-07-14
申请人： Osamu Ujikawa , Kazuaki Takami , Nobuyuki Takakura , Nozomu Sakai
发明人： Osamu Ujikawa , Kazuaki Takami , Nobuyuki Takakura , Nozomu Sakai
IPC分类号： C07F9/58 , C07D213/56 , C07D401/12 , C07D413/12
CPC分类号： C07F9/58 , A61K31/4418 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K31/675 , C07D213/56 , C07D401/12 , C07D413/12
摘要： The present invention provides a compound having a muscle cell or adipocyte differentiation regulating action, useful for the prophylaxis or treatment of diseases such as diabetes, obesity, dyslipidemia and the like, and the like, and having superior efficacy.The present invention provides a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof.
-
公开(公告)号：US08044049B2
公开(公告)日：2011-10-25
申请号：US12064903
申请日：2007-08-03
IPC分类号： C07D487/04 , A61K31/5025 , A61P35/00
CPC分类号： C07D487/04
摘要： The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof.A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.
摘要翻译： 本发明提供具有强激酶抑制活性的稠合杂环衍生物及其应用。 由式（I）表示的化合物：其中每个符号如说明书中所定义，除了特定化合物或其盐，以及含有作为激酶的化合物或其前药的药物（VEGFR，VEGFR2 ，PDGFR，Raf）抑制剂，血管发生抑制剂，用于预防或治疗癌症的药物，癌症生长抑制剂或癌症转移抑制剂。
-
公开(公告)号：US20090137595A1
公开(公告)日：2009-05-28
申请号：US12064903
申请日：2007-08-03
IPC分类号： A61K31/5025 , C07D487/04
CPC分类号： C07D487/04
摘要： The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof.A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.
-
公开(公告)号：US20050090534A1
公开(公告)日：2005-04-28
申请号：US10505742
申请日：2003-02-27
申请人： Nozomu Sakai , Yu Momose , Katsuhito Murase , Masatoshi Hazama
发明人： Nozomu Sakai , Yu Momose , Katsuhito Murase , Masatoshi Hazama
IPC分类号： A61P3/10 , A61P25/00 , A61P25/24 , A61P43/00 , C07D263/32 , C07D263/38 , C07D263/46 , C07D263/48 , C07D277/28 , C07D277/30 , C07D277/40 , C07D277/46 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/653 , C07F9/6539 , C07D417/02 , A61K31/4178 , A61K31/422 , A61K31/427 , C07D413/02 , C07D43/02
CPC分类号： C07D413/04 , C07D263/32 , C07D263/38 , C07D263/46 , C07D263/48 , C07D277/30 , C07D277/40 , C07D277/46 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/653 , C07F9/6539
摘要： The present invention provides a compound represented by the formula (I) wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group, A is an optionally substituted cyclic amino group or —NR2—W-D wherein R2 is a hydrogen atom or an alkyl group, W is a bond or a divalent acyclic hydrocarbon group, and D is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom, and Y is a bond or a divalent acyclic hydrocarbon group, or a salt thereof, which is useful for the prophylaxis or treatment of diabetic neuropathy and the like.
摘要翻译： 本发明提供由式（I）表示的化合物，其中R 1为氢原子，卤素原子，任选取代的烃基，任选取代的杂环基，任选取代的羟基， 任选取代的硫醇基或任选取代的氨基，A是任选取代的环氨基或-NR 2 -WD，其中R 2是氢原子或烷基 基团，W是键或二价无环烃基，D是任选取代的环状基团，任选取代的氨基或任选取代的酰基，B是任选取代的烃基或任选取代的杂环基，X是 氧原子，硫原子或任选取代的氮原子，Y是可用于预防或治疗糖尿病性神经病变等的键或二价无环烃基或其盐。
-
9.发明授权Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof 有权具有激酶抑制活性的咪唑并哒嗪衍生物及其药剂公开(公告)号：US08034812B2
公开(公告)日：2011-10-11
申请号：US12263884
申请日：2008-11-03
IPC分类号： C07D487/04 , A61K31/4985 , A61P35/00
CPC分类号： C07D487/04
摘要： The present invention provides an imidazopyridazine derivative compound having a potent kinase inhibitory activity and a pharmaceutical agent thereof useful for treatment or prevention of cancer and the like. One such compound is represented by the formula: or a salt thereof or a prodrug thereof. The pharmaceutical agent contains the imidazopyridazine derivative compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor, or a cancer metastasis suppressor.
摘要翻译： 本发明提供了可用于治疗或预防癌症等的具有强激酶抑制活性的咪唑并哒嗪衍生化合物及其药剂。 一种这样的化合物由下式表示：或其盐或其前药。 药剂含有作为激酶（VEGFR，VEGFR2，PDGFR，Raf）抑制剂，血管发生抑制剂，癌症预防或治疗剂，癌症生长抑制剂或癌症的咪唑并哒嗪衍生物化合物或其前药 转移抑制因子
-
公开(公告)号：US20080287438A1
公开(公告)日：2008-11-20
申请号：US12219073
申请日：2008-07-15
申请人： Yu Momose , Nozomu Sakai , Tsuyoshi Maekawa , Masatoshi Hazama , Toru Kawamura , Misayo Sera
发明人： Yu Momose , Nozomu Sakai , Tsuyoshi Maekawa , Masatoshi Hazama , Toru Kawamura , Misayo Sera
IPC分类号： A61K31/5377 , A61K31/4196 , A61K31/4164 , A61K31/4152 , C07D403/02 , A61K31/4439 , A61P25/00 , C07D401/02 , C07D249/12 , C07D233/00 , C07D413/02
CPC分类号： C07D231/12 , A61K31/402 , A61K31/415 , A61K31/4155 , A61K31/416 , A61K31/4174 , A61K31/4178 , A61K31/4184 , A61K31/427 , A61K31/4439 , A61K31/66 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12 , C07F9/4056 , C07F9/5537 , C07F9/65031 , C07F9/6506 , C07F9/6518 , C07F9/653 , C07F9/65395 , C07F9/65586 , C07F9/657181
摘要： The present invention provides an agent for preventing or treating neuropathy having superior action and low toxicity. This agent comprises a compound represented by the formula: wherein ring A is a 5-membered aromatic heterocycle containing 2 or more nitrogen atoms, which may further have substituent(s); B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a divalent acyclic hydrocarbon group; Z is —O—, —S—, —NR2—, —CONR2— or —NR2CO— (R2 is a hydrogen atom or an optionally substituted alkyl group); Y is a bond or a divalent acyclic hydrocarbon group; R1 is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, provided that when the 5-membered aromatic heterocycle represented by ring A is imidazole, then Z should not be —O—, or a salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.054 秒)
